Arthritis Clinical Trials

Find Arthritis Clinical Trials Near You

Evaluation of Ultralow Dose PET Imaging for Detecting 18F-NaF Uptake

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection, arthritis, and other benign diseases of bone detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-sodium fluoride (NaF) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 120
Healthy Volunteers: t
View:

• Age ≥18 years.

• Ability to provide informed consent and comply with study procedures.

• For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.

Locations
United States
New Jersey
Nuclear Imaging Institute
RECRUITING
Englewood
Nuclear Imaging Institute
ENROLLING_BY_INVITATION
Englewood
Contact Information
Primary
Barbara Blanchfield
bblanchfield@nii.org
973-255-4955
Time Frame
Start Date: 2025-09-01
Estimated Completion Date: 2030-06-30
Participants
Target number of participants: 200
Treatments
Other: ultralow dose 18F-NaF imaging group
Participants will be enrolled for an ultralow dose PET scan to evaluate image quality and optimize timing and reconstruction after reducing radiation doses 10-100 fold. Participants will be injected with a very small amount of radiotracer and imaged on a PET scanner for up to 3 hours
Related Therapeutic Areas
Sponsors
Leads: Akiva Mintz

This content was sourced from clinicaltrials.gov